William Blair has downgraded Exact Sciences Corp (EXAS) to Market Perform from Outperform as of November 20, 2025. This revision signals heightened caution regarding the company's future prospects.
Exact Sciences, a biotechnology firm based in Madison, Wisconsin, specializes in cancer screening and diagnostics. The company's flagship product, Cologuard, is a non-invasive stool-based DNA screening test designed for colorectal cancer detection. With a market capitalization of $12.7 billion, Exact Sciences employs approximately 6,900 full-time staff and has been focusing its research efforts on colorectal cancer screening, multi-cancer early detection (MCED), and minimal residual disease (MRD) tests.
The downgrade may reflect concerns about competitive pressures, market conditions, or execution risks that could influence the company's performance. As of the latest consensus on November 1, 2025, analysts remain generally positive, with 12 Strong Buy, 14 Buy, and 4 Hold ratings.
Upcoming earnings reports include estimates of $0.12 per share on revenues of $935.7 million for August 4, 2026. Recent performance has shown volatility, with the third quarter of 2025 reporting an EPS of -$0.10, falling short of the estimate of -$0.07.
Analyst ratings and price targets serve as professional insights based on extensive research. While they can provide valuable perspectives, they are subject to change as new information emerges. Investors should consider a range of factors, including company fundamentals and market trends, when making decisions.